{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:48:53Z","timestamp":1790887733213,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymgme.2020.12.295","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T06:20:24Z","timestamp":1610432424000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment"],"prefix":"10.1016","volume":"132","author":[{"given":"Neal J.","family":"Weinreb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jos\u00e9 Simon","family":"Camelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica R.","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.12.295_bb0005","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2014"},{"key":"10.1016\/j.ymgme.2020.12.295_bb0010","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher Disease: Phenotypic and genetic variation","author":"Grabowski","year":"2014"},{"issue":"3","key":"10.1016\/j.ymgme.2020.12.295_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","article-title":"\u2018Non-neuronopathic\u2019 Gaucher disease disease patients and a systematic review of the literature","volume":"31","author":"Biegstraaten","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"18","key":"10.1016\/j.ymgme.2020.12.295_bb0020","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher Registry: Demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2020.12.295_bb0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2020.12.295_bb0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"20","key":"10.1016\/j.ymgme.2020.12.295_bb0035","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ymgme.2020.12.295_bb0040","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int. J. Surg."},{"issue":"3","key":"10.1016\/j.ymgme.2020.12.295_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.25701","article-title":"The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease","volume":"95","author":"Drelichman","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.ymgme.2020.12.295_bb0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5639\/gabij.2019.0802.008","article-title":"Are there biosimilar orphan drugs for Gaucher disease? An overview in Mexico","volume":"8","author":"Esquivel-Aguilar","year":"2019","journal-title":"GaBI J."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0055","author":"CDC"},{"key":"10.1016\/j.ymgme.2020.12.295_bb0060","first-page":"1","article-title":"Mean body weight, height, waist crcumference, and body mass index among adults: United States, 1999-2000 through 2015-2016","volume":"122","author":"Fryar","year":"2018","journal-title":"Natl. Health Stat. Report."},{"issue":"3","key":"10.1016\/j.ymgme.2020.12.295_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","article-title":"Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring","volume":"31","author":"Cox","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2020.12.295_bb0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2007.06701.x","article-title":"Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease","volume":"138","author":"Hughes","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ymgme.2020.12.295_bb0075","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000489251","article-title":"Gaucher disease and myelofibrosis: a combined disease or a misdiagnosis?","volume":"139","author":"Mariani","year":"2018","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.ymgme.2020.12.295_bb0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bcmd.2010.09.007","article-title":"JAK2V617F mutation and myeloproliferative malignancy in a patient with type 1 Gaucher disease","volume":"46","author":"Webb","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2020.12.295_bb0085","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2141.2012.09175.x","article-title":"Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years","volume":"158","author":"Hollak","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.ymgme.2020.12.295_bb0090","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","article-title":"Hepatocellular carcinoma in Gaucher disease: An international case series","volume":"41","author":"Regenboog","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2020.12.295_bb0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ymgme.2018.08.004","article-title":"Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease","volume":"125","author":"Nascimbeni","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"4 Suppl 5","key":"10.1016\/j.ymgme.2020.12.295_bb0100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"issue":"2","key":"10.1016\/j.ymgme.2020.12.295_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beem.2014.08.006","article-title":"The attenuated\/late onset lysosomal storage disorders: therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease","volume":"29","author":"Hollak","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0110","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1148\/91.6.1195","article-title":"Relationship between liver size and body size","volume":"91","author":"DeLand","year":"1968","journal-title":"Radiology."},{"issue":"1","key":"10.1016\/j.ymgme.2020.12.295_bb0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1148\/radiol.2015150887","article-title":"Spleen size is significantly influenced by body height and sex: establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals","volume":"279","author":"Chow","year":"2016","journal-title":"Radiology."},{"issue":"1","key":"10.1016\/j.ymgme.2020.12.295_bb0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine."},{"issue":"6","key":"10.1016\/j.ymgme.2020.12.295_bb0125","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: from pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.ymgme.2020.12.295_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00223-014-9923-y","article-title":"Gaucher disease and bone manifestations","volume":"95","author":"Marcucci","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"Weinreb","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0140","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.24801","article-title":"Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase\/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.ymgme.2020.12.295_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11926-000-0059-x","article-title":"Bone and joint complications related to Gaucher disease","volume":"2","author":"Pastores","year":"2000","journal-title":"Curr. Rheumatol. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2020.12.295_bb0150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Spanish Group on Gaucher disease. Quality of life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0155","first-page":"117","article-title":"Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 Italian Gaucher type I patients","volume":"7","author":"Deroma","year":"2013","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2020.12.295_bb0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcmd.2010.05.002","article-title":"Enzyme replacement therapy \u201cdrug holiday\u201d: results from an unexpected shortage of an orphan drug supply in Australia","volume":"46","author":"Goldblatt","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2020.12.295_bb0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2010.05.001","article-title":"Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply","volume":"46","author":"Zimran","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2020.12.295_bb0170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet Med."},{"issue":"12","key":"10.1016\/j.ymgme.2020.12.295_bb0175","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ymgme.2020.12.295_bb0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-7075-10-34","article-title":"Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: A systematic review","volume":"10","author":"Doneda","year":"2013","journal-title":"Nutr. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2020.12.295_bb0185","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcmd.2016.11.014","article-title":"Growth and final height of children with Gaucher disease: A 15-year follow-up at an Israeli Gaucher center","volume":"68","author":"Mendelsohn","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2020.12.295_bb0195","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"40","author":"Langeveld","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14640","article-title":"Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease","author":"Nascimbeni","year":"2020","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.ymgme.2020.12.295_bb0205","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.3390\/jcm9082343","article-title":"A cross-sectional retrospective study of non-splenectomized and never-treated patients with type 1 Gaucher disease","volume":"9","author":"Serratrice","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2020.12.295_bb0210","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: Effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ymgme.2020.12.295_bb0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.12.295_bb0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcmd.2016.10.002","article-title":"Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy","volume":"68","author":"Weinreb","year":"2018","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:26:54Z","timestamp":1761089214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1096719221000019"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.295","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}